NCT05830240View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

March 27, 2025

Study Completion Date

March 27, 2026

Conditions
Head and Neck CancerEsophageal CancerOtorhinolaryngologic NeoplasmsEar CancerNose CancerLaryngeal CancerPharyngeal Cancer
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type 1 (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

200000

RECRUITING

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Eye & ENT Hospital of Fudan University

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY